Mercado global de servicios de seguridad cardíaca, por servicios (mediciones de ECG/Holter, mediciones de presión arterial , servicios de evaluación de seguridad cardíaca in vitro, imágenes cardiovasculares, monitoreo de telemetría en tiempo real, lectura centralizada de ECGS, imágenes cardíacas no invasivas, pruebas de estrés fisiológico, estudios exhaustivos de QT, TQT y modelado de respuesta a la exposición, agregación plaquetaria y otros servicios), fase (fase 1, fase 2 y fase 3), tipo (servicios integrados y servicios independientes), usuario final ( compañías farmacéuticas y biofarmacéuticas, organizaciones de investigación por contrato e institutos académicos y de investigación), tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado
El mercado mundial de servicios de seguridad cardíaca está impulsado por factores como el aumento del desarrollo de nuevos medicamentos, el creciente número de nuevos actores y la innovación en tecnología, que aumentan su demanda, así como el aumento de la inversión en investigación y desarrollo, lo que conduce al crecimiento del mercado. Actualmente, se están llevando a cabo varios estudios de investigación, lo que se espera que cree una ventaja competitiva para que los fabricantes desarrollen sistemas de servicios de seguridad cardíaca nuevos e innovadores, lo que se espera que brinde varias otras oportunidades en el mercado de servicios de seguridad cardíaca. Sin embargo, se espera que las estrictas regulaciones gubernamentales sobre la aprobación obstaculicen el crecimiento.
El informe de mercado global de servicios de seguridad cardíaca proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista, nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado. La escalabilidad y la expansión comercial de las unidades minoristas en los países en desarrollo de varias regiones y la asociación con proveedores para la distribución segura de productos de máquinas y medicamentos son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
El mercado mundial de servicios de seguridad cardíaca es favorable y tiene como objetivo reducir la progresión de la enfermedad. Data Bridge Market Research analiza que el mercado mundial de servicios de seguridad cardíaca crecerá a una tasa compuesta anual del 15,4 % durante el período de pronóstico de 2022 a 2029.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2022 a 2029 |
|
Año base |
2021 |
|
Años históricos |
2020 (Personalizable para 2019 - 2014) |
|
Unidades cuantitativas |
Ingresos en millones de USD, precios en USD |
|
Segmentos cubiertos |
By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) |
|
Countries Covered |
U.S., Canada, Mexico, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa, Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific |
|
Market Players Covered |
Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, Celerion, Biotrial, NEXEL Co., Ltd, Richmond Pharmacology, PhysioStim, Shanghai Medicilon Inc, Clario, PPD Inc among others. |
Market Definition
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Global Cardiac Safety Services Market Dynamics
Drivers
- Increase in the number of clinical trials
A clinical trial is a well-structured system that is way back hundreds of years and is still the backbone of the regulatory requirements required for a drug to be approved. Recently there has been much advancement in the clinical trial field, which has increased the number of clinical trials and is expected to propel the market growth.
There have been various changes in the regulatory of the clinical trials, which has increased the number of clinical trials and their positive results-
For instance,
- According to the article by Medical News, there has been a significant increase in the number of trials due to the rise in the quality of clinical trials, such as mandatory training of all staff. Also, in 2017, NIH stated that all investigators and staff should be trained on good clinical practice (GCP) in trials that NIH funds
Increase in healthcare expenditure and funding
La cantidad de dinero que un país utiliza en su atención de salud y su tasa de crecimiento a lo largo del tiempo están influenciadas por una amplia variedad de factores económicos y sociales, incluidos los acuerdos de financiamiento y la estructura de la organización del sistema de salud.
El gasto en atención sanitaria ha aumentado en los países desarrollados y las economías emergentes a medida que aumenta el ingreso disponible de las personas. Cuanto más dinero se gasta en atención sanitaria, más saludable es la población de un país.
Oportunidad
- Aumento del desarrollo de nuevos fármacos
Los ensayos clínicos son vitales para descubrir y desarrollar nuevos medicamentos para el tratamiento de enfermedades. Es la mejor manera en que los investigadores pueden averiguar qué tratamientos funcionan o no en los seres humanos. El desarrollo de medicamentos se caracteriza por la creación de nuevos tratamientos, como medicamentos o dispositivos para curar diversas enfermedades, como el cáncer, enfermedades endocrinas, metabólicas y otras.
- Por lo tanto, los ensayos clínicos son la forma más eficaz de garantizar la seguridad y eficacia del medicamento terapéutico antes de su lanzamiento al mercado y al consumo humano, lo que incluye la evaluación de la seguridad cardíaca, que es una parte esencial antes de que cualquier producto médico salga al mercado.
Restricción/Desafío
La evaluación y la presentación de informes adecuados sobre la seguridad cardíaca clínica son esenciales. La aprobación y el retiro de productos de cualquier producto médico dependen de la evaluación de la seguridad cardíaca. Por lo tanto, es necesario proporcionar y llevar a cabo una evaluación de la seguridad cardíaca de acuerdo con el procedimiento legal; de lo contrario, esto conduce a una aprobación tardía del producto, lo que se espera que frene el crecimiento del mercado.
Por ejemplo,
- Según el artículo de IQVIA, entre 1957 y 2007 se produjeron 47 casos de retirada de fármacos tras su comercialización, de los cuales el 45% se debió a problemas de toxicidad cardiovascular. De manera similar, el 27% de las posibles nuevas moléculas de fármacos que fracasaron en la fase preclínica en las dos últimas décadas lo hicieron por toxicidad cardiovascular, ya que no cumplían los requisitos regulatorios.
Segmentación del mercado global de servicios de seguridad cardíaca
El mercado global de servicios de seguridad cardíaca se clasifica en tipo, servicios, fase y usuario final. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
Servicios
- Mediciones de ECG /Holter
- Mediciones de presión arterial
- Servicios de evaluación de seguridad cardíaca in vitro
- Imágenes cardiovasculares
- Monitoreo de telemetría en tiempo real
- Lectura central del ECG
- Imágenes cardíacas no invasivas
- Prueba de estrés fisiológico
- Estudios exhaustivos del QT
- TQT y modelado de respuesta a la exposición
- Agregación plaquetaria
- Otros servicios
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services
Phase
- Phase 1
- Phase 2
- Phase 3
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2, and phase 3.
Type
- Integrated services
- Standalone services
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services.
End User
- Pharmaceuticals & Biopharmaceuticals Companies
- Contract Research Organizations
- Academic and Research Institute
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations, and academic and research institute.
Cardiac Safety Services Regional Analysis/Insights
The cardiac safety services are analysed and market size insights and trends are provided by type, services, phase and end user as referenced above.
The countries covered in the cardiac safety services report are U.S., Canada, Mexico, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa, Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific
The U.S. is expected to dominate due to increase in technological advancement in the developing areas.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cardiac Safety Services Analysis
El panorama competitivo del mercado mundial de servicios de seguridad cardíaca proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado de servicios de seguridad cardíaca.
Algunos de los principales actores del mercado son Koninklijke Philips NV, Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, Celerion, Biotrial, NEXEL Co., Ltd, Richmond Pharmacology, PhysioStim, Shanghai Medicilon Inc, Clario, PPD Inc entre otros.
Metodología de la investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con tamaños de muestra grandes. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Aparte de esto, los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de la línea de tiempo del mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de la participación de mercado de la empresa, estándares de medición, análisis global versus regional y de la participación de los proveedores. Solicite una llamada de un analista en caso de tener más consultas.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6 INDUSTRY INSIGHT
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.2 PATENT ANALYSIS
6.3 PATENT FLOW DIAGRAM
6.4 KEY PATIENT ENROLLMENT STRATEGIES
6.5 PRICING STRATEGY
7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS
8.1.4 INCREASE IN R&D ACTIVITIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION
8.2.2 STRICT REGULATORY
8.3 OPPORTUNITIES:
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES
8.4 CHALLENGES
8.4.1 TIME-CONSUMING PROCEDURE
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION
9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES
9.1 OVERVIEW
9.2 ECG/HOLTER MEASUREMENTS
9.3 BLOOD PRESSURE MEASUREMENTS
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS
9.4.1.1 1 CONCENTRATIONS
9.4.1.2 4 CONCENTRATIONS
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)
9.4.2.1 3 CONCENTRATIONS
9.4.2.2 5 CONCENTRATIONS
9.4.3 IN VITRO HERG ASSAY
9.4.4 OTHERS
9.5 CARDIOVASCULAR IMAGING
9.6 REAL TIME TELEMETRY MONITORING
9.7 CENTRAL OVER-READ OF ECGS
9.8 NON-INVASIVE CARDIAC IMAGING
9.9 PHYSIOLOGIC STRESS TESTING
9.1 THOROUGH QT STUDIES
9.11 TQT AND EXPOSURE RESPONSE MODELLING
9.12 PLATELET AGGREGATION
9.13 OTHERS
10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE
10.1 OVERVIEW
10.2 PHASE I
10.3 PHASE II
10.4 PHASE III
11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE
11.1 OVERVIEW
11.2 INTEGRATED SERVICES
11.3 STANDALONE SERVICES
12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER
12.1 OVERVIEW
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES
12.3 CONTRACT RESEARCH ORGANIZATIONS
12.4 ACADEMIC AND RESEARCH INSTITUTE
13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 SPAIN
13.3.6 TURKEY
13.3.7 RUSSIA
13.3.8 NETHERLANDS
13.3.9 SWITZERLAND
13.3.10 BELGIUM
13.3.11 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.2 JAPAN
13.4.3 SOUTH KOREA
13.4.4 INDIA
13.4.5 AUSTRALIA
13.4.6 SINGAPORE
13.4.7 THAILAND
13.4.8 MALAYSIA
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 SAUDI ARABIA
13.6.3 U.A.E.
13.6.4 ISRAEL
13.6.5 EGYPT
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 COMPANY PROFILE
15.1 EUROFINS SCIENTIFIC
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.1.5.1 AGREEMENTS
15.1.5.2 ACQUISITION
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC)
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 INVESTMENT
15.3 KONINKLIJKE PHILIPS N.V.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 IQVIA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.4.5.1 ACQUISITION
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 NEW LABORATORY
15.5.5.2 ACQUISITION
15.6 BANOOK
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.6.3.1 AGREEMENT
15.7 BIOTRIAL
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.7.3.1 NEW CENTER OPENING
15.8 CELERION
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.8.3.1 NEW CENTER OPENING
15.9 CERTARA
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 CONTRACT
15.9.4.2 ACQUISITION
15.1 CLARIO
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 PRODUCT EXPANSION
15.11 MEDPACE
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENTS
15.11.4.1 ACQUISITION
15.12 NCARDIA
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.12.3.1 PARTNERSHIP
15.13 NEXEL CO., LTD
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.13.3.1 JOINT VENTURE
15.13.3.2 PARTNERSHIP
15.14 PHYSIOSTIM
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.14.3.1 PARTNERSHIP
15.15 RICHMOND PHARMACOLOGY
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.15.3.1 EVENT
15.16 SGS SA
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.16.4.1 ACQUISITION
15.17 SHANGHAI MEDICILON INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 PARTNERSHIP
15.17.3.2 PARTNERSHIP
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tablas
TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA
TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE)
TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION
TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS
TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES
TABLE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 GLOBAL INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 GLOBAL STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 GLOBAL PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 GLOBAL ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 U.S. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 45 U.S. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 46 U.S. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 47 U.S. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 48 U.S. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 49 U.S. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 CANADA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 52 CANADA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 53 CANADA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 54 CANADA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 55 CANADA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 56 CANADA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 CANADA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 MEXICO CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 59 MEXICO IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 60 MEXICO HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 61 MEXICO COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 62 MEXICO CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 63 MEXICO CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 MEXICO CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 66 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 67 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 68 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 69 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 70 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 71 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 74 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 75 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 76 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 77 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 78 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 81 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 82 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 83 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 84 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 85 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 87 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 88 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 89 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 90 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 91 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 92 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 95 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 96 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 97 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 98 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 99 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 101 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 102 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 103 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 104 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 105 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 106 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 108 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 109 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 110 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 111 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 112 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 113 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 120 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 123 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 124 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 130 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 131 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 134 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 136 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 137 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 138 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 139 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 140 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 141 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 143 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 144 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 145 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 146 ASIA-PACIFIC IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 147 ASIA-PACIFIC HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 148 ASIA-PACIFIC COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 149 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 150 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 CHINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 153 CHINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 154 CHINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 155 CHINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 156 CHINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 157 CHINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 CHINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 159 JAPAN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 160 JAPAN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 161 JAPAN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 162 JAPAN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 163 JAPAN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 164 JAPAN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 JAPAN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 167 SOUTH KOREA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 168 SOUTH KOREA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 169 SOUTH KOREA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 170 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 171 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SOUTH KOREA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 173 INDIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 174 INDIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 175 INDIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 176 INDIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 177 INDIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 178 INDIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 INDIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 180 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 181 AUSTRALIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 182 AUSTRALIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 183 AUSTRALIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 184 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 185 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 AUSTRALIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 188 SINGAPORE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 189 SINGAPORE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 190 SINGAPORE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 191 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 192 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 SINGAPORE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 THAILAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 195 THAILAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 196 THAILAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 197 THAILAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 198 THAILAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 199 THAILAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 THAILAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 201 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 202 MALAYSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 203 MALAYSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 204 MALAYSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 205 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 206 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 MALAYSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 209 INDONESIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 210 INDONESIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 211 INDONESIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 212 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 213 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 INDONESIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 215 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 216 PHILIPPINES IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 217 PHILIPPINES HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 218 PHILIPPINES COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 219 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 220 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 PHILIPPINES CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 REST OF ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 223 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 224 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 225 SOUTH AMERICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 226 SOUTH AMERICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 227 SOUTH AMERICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 228 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 229 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 231 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 232 BRAZIL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 233 BRAZIL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 234 BRAZIL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 235 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 236 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 BRAZIL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 238 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 239 ARGENTINA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 240 ARGENTINA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 241 ARGENTINA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 242 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 243 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 ARGENTINA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 245 REST OF SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 246 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 247 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 248 MIDDLE EAST AND AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 249 MIDDLE EAST AND AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 250 MIDDLE EAST AND AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 251 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 252 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 253 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 254 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 255 SOUTH AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 256 SOUTH AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 257 SOUTH AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 258 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 259 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 261 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 262 SAUDI ARABIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 263 SAUDI ARABIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 264 SAUDI ARABIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 265 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 266 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 268 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 269 U.A.E. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 270 U.A.E. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 271 U.A.E. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 272 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 273 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 275 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 276 ISRAEL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 277 ISRAEL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 278 ISRAEL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 279 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 280 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 281 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 282 EGYPT CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 283 EGYPT IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 284 EGYPT HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 285 EGYPT COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 286 EGYPT CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 287 EGYPT CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 EGYPT CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 289 REST OF MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 2 GLOBAL CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CARDIAC SAFETY SERVICES MARKET: GLOBAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID
FIGURE 9 GLOBAL CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029
FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL CARDIAC SAFETY SERVICES MARKET
FIGURE 15 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021
FIGURE 16 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION)
FIGURE 17 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029)
FIGURE 18 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE
FIGURE 19 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021
FIGURE 20 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION)
FIGURE 21 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029)
FIGURE 22 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE
FIGURE 23 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021
FIGURE 24 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 25 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 26 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021
FIGURE 28 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 GLOBAL CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 32 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021)
FIGURE 33 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2022 & 2029)
FIGURE 34 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY REGION (2021 & 2029)
FIGURE 35 GLOBAL CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 36 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 37 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 38 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 39 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 40 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 41 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 42 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 43 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 44 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 45 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 46 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 47 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 48 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 49 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 50 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 51 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 52 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 53 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 SOUTH AMERICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 56 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 57 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 58 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 59 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 60 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 61 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 62 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 63 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 ASIA-PACIFIC CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
